This study has two parts. In the first part, researchers test different dose levels of a new medicine called BBO 11818 to find the safest and best dose. Some people will receive BBO 11818 by itself, while others will receive it together with other cancer medicines. The treatment group depends on the type of cancer and the specific KRAS gene change a person has.

In the second part, more people will receive the dose that was found to be safe in the first part. Researchers will study BBO 11818 by itself and in combination with other treatments in different groups of patients. The goal is to learn more about how safe the medicine is, what side effects it may cause, and whether it can help slow or shrink cancers with specific KRAS gene changes.

This study is for people who have advanced cancer that has spread or cannot be removed with surgery. The cancers may include non small cell lung cancer, colorectal cancer, pancreatic cancer, or other solid tumors. Participants must have a specific change in a gene called KRAS. Researchers are studying new treatments that target cancers with these KRAS gene changes to learn if they can help control cancer growth and improve outcomes for patients.

People may be able to join this study if they are adults and are willing to attend study visits and follow study instructions. They must have advanced cancer that has spread, cannot be removed with surgery, or cannot be fully treated with radiation. Participants must have at least one tumor that can be measured on scans so doctors can track changes during the study. They should also be expected to live for at least a few more months so researchers can safely study how the treatment affects their cancer.

This study is testing a new medicine called BBO 11818 for people with advanced cancers that have certain KRAS gene changes. Researchers want to find the safest and best dose of BBO 11818 when it is given by itself and when it is combined with other cancer treatments.

The study will also look at both the helpful and harmful effects of the medicine. BBO 11818 may be given alone or together with other cancer medicines, including immunotherapy and chemotherapy drugs. The goal is to learn if this new treatment can help control cancer and improve future treatment options for people with advanced solid tumors.